Two types of structural alterations of the JAK2 kinase -point mutation and rearrangement following t(8;9) translocationhave been recently found in myeloproliferative disorders and acute leukaemias. [1] [2] [3] [4] [5] We now report the characterisation of a t(8;9)(p22;p24) with PCM1-JAK2 gene fusion in a T-cell lymphoma.
A 40-year-old man was referred to the haematological unit for cervical and axillar lymphadenopathy in September 1998. He presented with large peripheral lymphadenopathies in all areas; the ECOG score was 4. The leukocyte count, haemoglobin level and platelet count were normal as well as LDH. The computed tomography scan of thorax, abdomen and pelvis showed small retroperitoneal lymphadenopathies. The lymph-node biopsy showed infiltration with abnormal CD2 þ , CD3 þ , CD7 þ , CD4À, CD5À, CD8À, CD1A low lymphocytes, with a high index of proliferation. Bone marrow (BM) aspiration and biopsy were normal. The diagnosis was lymphoblastic T lymphoma IIIBa. Induction chemotherapy based on acute lymphoblastic leukaemia (ALL) chemotherapy (association of vincristin, anthracyclin, cyclophosphamide and steroid) allowed complete remission (CR). The patient received four courses of consolidation chemotherapy, 18-gray central nervous system radiotherapy and 2 year-maintenance chemotherapy. Peripheral blood stem cells were collected and stored after chemotherapy and G-CSF.
Figure 1
Characterisation of PCM1-JAK2 fusion in patient (P) with t(8;9)(p22;p24). Schematic representation of JAK2 protein, with its functional domains. B41, SH2, JH2 and TK are band 4.1, SRC-homology 2, pseudo-kinase and kinase domains, respectively. Nucleotide (cDNA level) and amino-acid sequences are positioned above and below the protein, respectively. Breakpoints targeting PCM1 and JAK2 in different documented cases of t(8;9)(p22;p24) [1] [2] [3] are shown by arrowheads. The present case is indicated by P arrowheads. V617F mutation associated with classical myeloproliferative disorders 5 is indicated by a lozenge. Inset: PCM1-JAK2 fusion transcripts were detected as RT-PCR fragments in lymphnode cells of the patient in 2004 (890 bp) and in a previously analysed patient 2 as positive control (1077 bp). PCR from June 2005, blood and BM cells were negative. JAK2-PCM1, PCM1 and JAK2 transcripts were also detected. NCOA2 PCR amplification was used as control.
Six years after CR and 38 months after the end of the chemotherapy, the patient presented a relapse with lymphadenopathies without central nervous or BM localisation. Cytogenetic analysis on BM cells after 24 h culture showed a t(8;9) translocation as a sole abnormality in 16/29 metaphases. A novel lymph-node biopsy confirmed the relapse of T lymphoblastic lymphoma with a TDT þ , CD2 þ , CD3 þ , CD4À, CD5 þ , CD7 þ , CD8À, CD10À, CD30À, CD1AÀ, KITÀ phenotype, and P53 moderate overexpression. A high mitotic activity was evidenced with MIB1 antibody. The search for an association with Epstein-Barr virus was negative with LMP antibody. A second CR was obtained after ALL-like induction chemotherapy with the same drugs plus L-asparaginase. After three courses of consolidation including high doses aracytine and methotrexate, autologous stem cell transplantation was done in February 2005. The patient is still in CR 7 months after the graft and the karyotype established on BM in June 2005 was normal on 30 metaphases.
Dual-colour fluorescence in situ hybridisation, carried out as described 2 on BM metaphasic cells from November 2004, showed the t(8;9)(p22;p24) rearrangement. RT-PCR analysis, carried out as previously described, 1-3 demonstrated the PCM1-JAK2 gene fusion in lymph-node cells of the patient in September 2004, but not on BM or blood cells in CR. Both PCM1-JAK2 and JAK2-PCM1 transcripts were observed (Figure 1 , inset). The breakpoint was localised in JAK2 intron 8 and both the JH2 pseudo-kinase domain and tyrosine kinase domain were preserved (Figure 1) .
The PCM1-JAK2 fusion has been described recently in a pre-B ALL. 1 We have reported here the first case of this alteration in a T-cell lymphoma. Our work shows that the spectrum of JAK2 activation may be quite large and include both lymphocyte lineages. In the reported case, the presence of the t(8;9) in peripheral lymphocytes and in BM cells suggests the targeting of the totipotent stem cells. 
